Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin launches Ganirelix Acetate Injection in US
Details : Ganirelix Acetate-Generic is a synthetic decapeptide used to prevent premature LH surges during controlled ovarian hyperstimulation.
Product Name : Ganirelix Acetate-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment
Details : Ganirelix Acetate Injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Product Name : Antagonä-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2023
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®
Details : Ganirelix Acetate is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 13, 2017
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Delayed Start to Ovarian Stimulation
Details : Ganirelix Acetate is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diminished Ovarian Reserve.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 07, 2012
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganirelix
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs
Details : Ganirelix is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2011
Lead Product(s) : Ganirelix
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
